CTOs on the Move

Baptist East/Milestone Wellness Ctr.

www.baptistmilestone.com

 
Fitness classes, lap pool, personal training, weight-loss programs, Pilates, weight training and more. Free mini-membership. All ages and fitness levels welcome.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Beta Health Association

Beta Health Association is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HomeCare Resources

HomeCare Resources is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coast Medical Service

With over 40 years in business, Coast Medical Service is LA’s premier nurse staffing agency serving hospitals, per diem nurses and travel nurses. Learn more.

Heal

Heal brings a licensed, background-checked pediatrician or family doctor to you, on-demand, on your schedule, for $99 or in-network with your insurance. Great doctors are available in Los Angeles, Orange County, Silicon Valley, San Diego and San Francisco from 8am to 8pm, seven days a week.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.